Loading
A phase 2 trial of NWRD06 administered by electroporation in hepatocellular carcinoma, run by Newish Technology (Beijing) Co., Ltd., now recruiting.
NWRD06 DNA Plasmid for HCC After Curative Resection. is a phase 2 interventional study registered as NCT07324304 by Newish Technology (Beijing) Co., Ltd., with 30 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12-31. Interventions recorded: NWRD06 administered by electroporation.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/